Effect of the pH grade of silicates on chemical stability of coground amorphous quinapril hydrochloride and its stabilization using pH-modifiers

Journal of Pharmaceutical Sciences

Volumn 98, Issue 9, 2009, Pages 3358-3372

  Hailu, Shumet A ^a   Bogner, Robin H ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Amorphous; Chemical stability; Cogrinding; Milling; pH grade of silicates; pH modifiers; Quinapril hydrochloride; Silicates; Stability; Stabilization

Indexed keywords

AEROSIL; ASCORBIC ACID; MAGNESIUM OXIDE; NEUSILIN; PIPERAZINEDIONE; QUINAPRIL; SILICATE; UNCLASSIFIED DRUG;

ARTICLE; CYCLIZATION; DRUG DEGRADATION; DRUG STABILITY; HYDROLYSIS; MICROSCOPY; PH; SURFACE PROPERTY; X RAY POWDER DIFFRACTION;

EID: 68949084952     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21767     Document Type: Article

References (31)

1. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397-404.
2. Kinoshita M, Baba K, Nagayasu A, Yamabe K, Shimooka T, Takeichi Y, Azuma M, Houchi H, Minakuchi K. 2002. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J Pharm Sci 91:362-370. (Pubitemid 34137358)
3. Bahl D, Bogner Robin H. 2008. Amorphization alone does not account for the enhancement of solubility of drug co-ground with silicate: The case of indomethacin. AAPS PharmSciTech 9:146-153.
4. Bahl D, Hudak J, Bogner RH. 2008. Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding. Pharm Dev Technol 13:255-269. (Pubitemid 351882244)
5. Byrn SR, Xu W, Newman AW. 2001. Chemical reactivity in solid-state pharmaceuticals: Formulation implications. Adv Drug Deliv Rev 48:115-136. (Pubitemid 32452294)
6. Pikal MJ, Lukes AL, Lang JE, Gaines K. 1978. Quantitative crystallinity determinations for b-lactam antibiotics by solution calorimetry: Correlations with stability. J Pharm Sci 67:767-773. (Pubitemid 8355230)
7. Wei X. 1997. Investigation of solid-state stability of selected bioactive compounds. ed., West Lafayette, IN 47907: PhD Thesis, Purdue University.
8. Yonemochi E, Matsumura M, Oguchi T, Yamamoto K, Nakai Y. 1991. Stability of aspirin in controlled pore glass solid dispersion. Chem Pharm Bull 39:1027-1031.
9. Rowe RC, Sheskey P, Weller PJ. 2003. Handbook of pharmaceutical excipients. 4th edition. London: Pharmaceutical Press and: Washington, DC: American Pharmaceutical Association.
10. Konno T. 1986. Physical and chemical changes of medicinals in mixtures with adsorbents in the solid state. I. Effect of vapor pressure of the medicinals on changes in crystalline properties. Chem Pharm Bull 34:301-307.
11. Konno T. 1990. Physical and chemical changes of medicinals in mixtures with adsorbents in the solid state. IV. Study on reduced-pressure mixing for practical use of amorphous mixtures of flufenamic acid. Chem Pharm Bull 38:2003-2007.
12. Gupta MK, Vanwert A, Bogner RH. 2003. Formation of physically stable amorphous drugs by milling with Neusilin. J Pharm Sci 92:536-551. (Pubitemid 36258968)
13. Bahl D, Bogner RH. 2006. Amorphization of indomethacin by co-grinding with Neusilin U S2: Amorphization kinetics, physical stability and mechanism. Pharm Res 23:2317-2325. (Pubitemid 44511512)
14. Watanabe T, Wakiyama N, Usui F, Ikeda M, Isobe T, Senna M. 2001. Stability of amorphous indomethacin compounded with silica. Int J Pharm 226:81-91. (Pubitemid 32800785)
15. Lau-Cam CA, Pendharkar CM, Jarowski CI, Yang KY. 1991. Instability of digoxin-amorphous silicon dioxide triturates prepared by solvent deposition and ball milling. Pharmazie 46:522-525.
16. Daniels R, Kerstiens B, Tischinger-Wagner H, Rupprecht H. 1989. The stability of drug adsorbates on to silica. In: Rubinstein MH, editor. Pharmaceutical technology drug stability. Chichester, England: Ellis Horwood Limited. pp. 49-67.
17. Daniels R, Rupprecht H. 1985. Adsorption and chemical stability of a cationic aggregating ester-propantheline bromide-on silica surfaces in aqueous dispersions. Pharm Res 2:170-175. (Pubitemid 15059600)
18. Gore A, Banker G. 1979. Surface chemistry of colloidal silica and a possible application to stabilize aspirin in solid matrix. J Pharm Sci 68:197-202. (Pubitemid 9117125)
19. Guo Y, Byrn SR, Zografi G. 2000. Physical characteristics and chemical degradation of amorphous quinapril hydrochloride. J Pharm Sci 89:128-143. (Pubitemid 30080161)
20. USP. 2008. Reagents, indicators and solutions. USP, the official compendia of standards, USP 31. Vol.1. Rockville, MD: United States Pharmacopeial Convention Inc. pp. 813-814.
21. Guo Y, Byrn SR, Zografi G. 2000. Effects of lyophilization on the physical characteristics and chemical stability of amorphous quinapril hydrochloride. Pharm Res 17:930-936. (Pubitemid 30736594)
22. Hausin RJ, Codding PW. 1991. Molecular and crystal structures of MDL27,467A hydrochloride and quinapril hydrochloride, two ester derivatives of potent angiotensin converting enzyme inhibitors. J Med Chem 34:511-517.
23. Theng G. 1981. Clay-activated organic reactions. In: Van-Olphen H, Veniale F, editors. International Clay Conference. Vol.35. Bologna and Pavia, Italy: Elsevier. pp. 197-238.
24. Zhuravlev LT. 1987. Concentration of hydroxyl groups on the surface of amorphous silicas. Langmuir 3:316-318.
25. Gu L, Strickley RG. 1987. Diketopiperazine formation, hydrolysis, and epimerization of the new dipeptide angiotensin-converting enzyme inhibitor RS-10085. Pharm Res 4:392-397. (Pubitemid 18010568)
26. Gu L, Strickley RG. 1988. Preformulation stability studies of the new dipeptide angiotensin-converting enzyme inhibitor RS-10029. Pharm Res 5:765-771. (Pubitemid 19060805)
27. Strickley RG, Visor GC, Lin L-H, Gu L. 1989. An unexpected pH effect on the stability of moexipril lyophilized powder. Pharm Res 6:971-975. (Pubitemid 20078450)
28. Bundgaard H, Falch E. 1985. Allopurinol prodrugs. I. Synthesis, stability and physicochemical properties of various N1-acyl allopurinol derivatives. Int J Pharm 23:223-237. (Pubitemid 15127906)
29. Glombitza BW, Oelkrug D, Schmidt PC. 1994. Surface acidity of solid pharmaceutical excipients. Part 1. Determination of the surface acidity. Eur J Pharm Biopharm 40:289-293. (Pubitemid 24342913)
30. Govindarajan R, Zinchuk A, Hancock B, Shalaev E, Suryanarayanan R. 2006. Ionization states in the microenvironment of solid dosage forms: Effect of formulation variables and processing. Pharm Res 23:2454-2468. (Pubitemid 44511524)
31. Li J, Guo Y, Zografi G. 2002. Effects of a citrate buffer system on the solid-state chemical stability of lyophilized quinapril preparations. Pharm Res 19:20-26. (Pubitemid 34075102)